Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vebicorvir (Primary) ; Entecavir; Tenofovir alafenamide; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Proof of concept; Therapeutic Use
Sponsors Assembly Biosciences

26 Jun 2022 Results assessing clinical evaluation of VBR 's drug-drug interaction (DDI) potential from Phase 1 (Study 103 ) and Phase 2a (NCT03577171, NCT03576066) studies, presented at The International Liver Congress 2022.
08 Jun 2022 According to an Assembly Biosciences media release, data from this study will be presented at the International Liver Congress, the Annual Meeting of the European Association for the Study of the Liver (EASL).
20 Apr 2022 Results published in the Journal of Hepatology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com